De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial (TRANSITION‐T2D). 
Rodriguez P, Breslaw N, Xiao H et al. 
Diabetes Obes Metab. 2024.
https://doi.org/10.1111/dom.16057